Clinical trials: Caffeine
Shoulder Arthroplasty and Fracture Repair
Tornier Shoulder Outcomes Study to Examine Safety and Functional Outcomes in Shoulder Arthroplasty and Fracture Patients
The Tornier Shoulder Outcomes Study is designed to collect safety and efficacy data on designated commercially available Tornier Shoulder repair products.
- Trial name
- NCT02047955
- Testing
- Shoulder Arthroplasty
- Where
- 15 sites in United States
- Volunteers
- 7,500 people
- Sponsor
- Stryker Trauma and Extremities
Drug Interaction
Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport
This is a single center, open-label, fixed sequence Phase 1, drug-drug interaction (DDI) study in healthy subjects.
- Trial name
- NCT05334108
- Testing
- Ecopipam, Cohort 1 Probe Substrate Cocktail, Cohort 2 Probe Substrate
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Emalex Biosciences Inc.
Relapsing-Remitting Multiple Sclerosis
An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis
The primary objective of the study is to assess the immunogenicity of Daclizumab High Yield Process (DAC HYP) 150 mg administered every 4 weeks by subcutaneous (SC) injection using the pre-filled syringe (PFS) in participants…
- Trial name
- OBSERVE (NCT01462318)
- Testing
- Midazolam, Caffeine, S-warfarin
- Where
- 19 sites in United States, Czechia and 2 more
- Volunteers
- 133 people
- Sponsor
- Biogen
Vascular Function
Effect of Black Tea on Vascular Function
Epidemiological studies indicate that regular consumption of three cups of black tea per day reduces the risk of stroke or myocardial infarction.
- Trial name
- Heraclitus (NCT01945970)
- Testing
- Black tea extract, Positive control
- Where
- Italy
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Unilever R&D
Neoplasms
Pharmacokinetic Drug-Drug Interaction Study of Rucaparib
The purpose of this study is to assess pharmacokinetic concentrations of multiple probes alone followed by assessment of the same drug pharmacokinetic concentrations when the patient has steady-state exposure to rucaparib…
- Trial name
- DDI (NCT02740712)
- Testing
- Caffeine, Warfarin, Omeprazole
- Where
- 3 sites in Poland
- Volunteers
- 17 people
- Sponsor
- pharmaand GmbH
Alcoholic Liver Cirrhosis
REVIVE(Randomized Exploratory Clinical Trial to Evaluate the Safety and Effectiveness of Stem Cell Product in Alcoholic Liver Cirrhosis Patient)
If the participant voluntarily agrees to participate in the clinical trial before registration, the investigator conducts a screening test to evaluate the participant's suitability.
- Trial name
- NCT01875081
- Testing
- Livercellgram
- Where
- South Korea
- Volunteers
- 72 people
- Sponsor
- Pharmicell Co., Ltd.
Depressive Disorder
Bupropion & Cardio Birth Defect (Slone)
Bupropion is a unique drug that is used both to treat depression and as an aid in smoking cessation. In 2008, the final report from the Bupropion pregnancy registry described 24 congenital malformations among the 675 women…
- Trial name
- NCT01597661
- Testing
- Exposure to any bupropion during the first trimester, Exposure to bupropion alone during the first trimester, Referent group: no exposure to any anti-depressant or anti-smoking drug during pregnancy
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Healthy Volunteers
A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants
The purpose of this study is to assess the effect of BMS-986419 on the pharmacokinetics (PK) of single doses of caffeine (CYP1A2 substrate), bupropion (CYP2B6 substrate), midazolam (CYP3A4 substrate), flurbiprofen (CYP2C9…
- Trial name
- NCT05932277
- Testing
- BMS-986419, Caffeine, Bupropion
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy Adults
This is an open-label, single sequence study that is being conducted to investigate the potential drug-drug interaction (DDI) when GSK3640254 is co-administered with a cocktail of cytochrome P450 (CYP) enzymes and transporter…
- Trial name
- NCT04425902
- Testing
- GSK3640254 200 mg, Caffeine 200 mg, Metoprolol 100 mg
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Solid Tumor Malignancies
A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor Malignancies
The purpose of this study is to evaluate the potential inhibitory effects of ASA404 on CYP1A2, CYP2C9, CYP3A4 and CYP2C19 mediated metabolism on the respective probe drugs caffeine, diclofenac, simvastatin, and omeprazole…
- Trial name
- NCT01290380
- Testing
- ASA404, DMXAA, DXAA
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Irritable Bowel Syndrome
Diets in Symptom Relief and the Influence of Quality of Life in People With Irritable Bowel Syndrome
Subjects with confirmed diagnosis of Irritable Bowel Syndrome will be blinded and randomly assigned to one of two groups, the low FODMAP diet or the conventional IBS diet group.
- Trial name
- NCT02450370
- Testing
- Low FODMAP diet, Conventional IBS diet group
- Where
- Hong Kong
- Volunteers
- 103 people
- Sponsor
- Hong Kong Sanatorium & Hospital
Drug Interactions
Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects
This is a Phase 1, open-label, fixed-sequence, 2-part DDI study. Subjects will participate in only 1 study part.
- Trial name
- NCT05657613
- Testing
- CYP450 Cocktail and Transporter Substrates with Pacritinib, Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib, Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- CTI BioPharma
Migraine Disorders
Acetylsalicylic Acid (ASA) + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache Patients
To confirm the combination rationale for the combination of ASA + paracetamol + caffeine compared with the combination of ASA + paracetamol and the individual substances ASA, paracetamol, caffeine, and placebo administered orally…
- Trial name
- NCT02183688
- Testing
- Low dose ASA, High dose ASA, Low dose paracetamol
- Volunteers
- 1,889 people
- Sponsor
- Boehringer Ingelheim
Drug Reactions
Effects of Repeated Doses of Lu AF35700 on Drug Metabolizing Enzymes
This study will help determine which types of drugs that may interact with Lu AF35700
- Trial name
- NCT03195946
- Testing
- Lu AF35700, Midazolam, Cocktail of CYP450 substrates
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Health Behavior
The Effects of a Personalized Sleep Improvement App From SleepScore Labs
The study is a single-blinded randomized waitlist controlled trial that aims to assess changes in objective and self-report sleep improvement through use of a dynamic and personalized sleep improvement smartphone app and advice…
- Trial name
- NCT05195359
- Testing
- Dein Schlaf. Dein Tag. sleep improvement application powered by SleepScore
- Where
- Germany
- Volunteers
- 637 people, healthy volunteers welcome
- Sponsor
- ResMed
Postoperative Dental Pain
A Study to Learn How Well a Single Dose of the Study Treatment Naproxen Sodium and Caffeine Combined in One Tablet (Fixed-dose Combination) Works to Relieve Pain After Dental Surgeries Compared to the Single Ingredients and to Placebo
Researchers are looking for a better way to relieve pain in people, such as after dental surgery. Participants in this study, have had 3 or 4 third molars (cheek teeth) removed and subsequently have moderate to severe tooth pain.
- Trial name
- NCT05485805
- Testing
- Naproxen sodium and caffeine (BAY2880376), Naproxen sodium (Aleve), Caffeine
- Where
- United States
- Volunteers
- 541 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy
Effects of Tipranavir (With Ritonavir) Capsule and Liquid Formulation on Cytochrome P450 and P-glycoprotein Activity in Healthy Volunteers
Primary: To quantify the influence of single-dose and steady-state tipranavir/ritonavir 500/200 mg on intestinal and hepatic cytochrome P450 (CYP) and P-glycoprotein (P-gp) biomarkers, as a means of predicting drug interactions.
- Trial name
- NCT02243553
- Testing
- Tipranavir capsule, Tipranavir solution, Ritonavir capsule
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Acute Coronary Syndrome
IDE-ALERTS Continued Access Study
This Continued Access IDE Study includes a subset of former ALERTS trial (NCT00781118) patients and provides performance data for a refined Guardian implantable medical device (AMSG3-E) with a new battery designed to extend…
- Trial name
- ALERTS-CAS (NCT04316481)
- Testing
- AngelMed Guardian System
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Angel Medical Systems
Skill Performance, Soccer Performance
Influence of Coffeeberry Ingestion on Soccer Skill Performance
The study of soccer skill performance has 3 objectives. Objective 1 is to compare effects of coffeeberry (300mg) and placebo ingestion on dribbling speed and precision and passing and shooting speed and accuracy compared to…
- Conditions
- Skill Performance, Soccer Performance, Coffeeberry Effects
- Trial name
- NCT04181619
- Testing
- Coffeeberry beverage, Comparator beverage
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- PepsiCo Global R&D
Polycythemia Vera
Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)
This is a Phase 2 study with an open-label dose escalation phase followed by a blinded withdrawal phase and an open label extension.
- Trial name
- NCT04057040
- Testing
- PTG-300
- Where
- 16 sites in United States, India
- Volunteers
- 70 people
- Sponsor
- Protagonist Therapeutics, Inc.